Evidence map›Paper›PMID 29529230›Full record

ArticleThe Journal of infectious diseases2018

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.

Monica Gandhi, Rajesh T Gandhi, Andrei Stefanescu, Ronald J Bosch, Joshua C Cyktor, Howard Horng, Alexander Louie, Nhi Phung, Joseph J Eron, Evelyn Hogg and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Observational
  15. Article
  16. Reply to Suthar et al.The Journal of infectious diseases · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Monica GandhiDepartment of Medicine, University of California San Francisco.
Rajesh T GandhiDepartment of Medicine and Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Andrei StefanescuHarvard T.H. Chan School of Public Health, Boston, MA.
Ronald J BoschHarvard T.H. Chan School of Public Health, Boston, MA.
Joshua C CyktorDepartment of Medicine, University of Pittsburgh, PA.
Howard HorngDepartment of Medicine, University of California San Francisco.
Alexander LouieDepartment of Medicine, University of California San Francisco.
Nhi PhungDepartment of Medicine, University of California San Francisco.
Joseph J EronDepartment of Medicine, University of North Carolina, Chapel Hill.
Evelyn HoggSocial and Scientific Systems, Inc., Silver Spring, MD.
Bernard J C MacatangayDepartment of Medicine, University of Pittsburgh, PA.
Christopher HenselFrontier Science and Technology Research Foundation, Inc., Amherst, NY.
Courtney V FletcherCollege of Pharmacy, University of Nebraska Medical Center, Omaha.
John W MellorsDepartment of Medicine, University of Pittsburgh, PA.
Deborah K McMahonDepartment of Medicine, University of Pittsburgh, PA.
A5321 Team
University of California, San Francisco · USUniversity of Pittsburgh · USHarvard University · USFrontier Science & Technology Research Foundation · USMassachusetts General Hospital · USSocial and Scientific Systems (United States) · USUniversity of Nebraska Medical Center · USUniversity of North Carolina at Chapel Hill · US

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
UNC MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146194 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Bradley Drummond, Michelle Floris-Moore · 2019 to 2026
$23.2M
University of Puerto Rico Clinical Trials UnitUM1AI069415 · NIAID · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FEBO, IRMA LUZ, SANTANA-BAGUR, JORGE L. · 2012 to 2021
$15.2M
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
NHLBI NIH HHS U01 HL146194NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI098472NIAID NIH HHS R37 AI098472NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

Data on the relationship of antiretroviral exposure to measures of human immunodeficiency virus (HIV) persistence are limited. To address this gap, multiple viral, immunologic, and pharmacologic measures were analyzed from individuals with sustained virologic suppression on therapy (median 7 years) in the AIDS Clinical Trials Group A5321 cohort. Among 110 participants on tenofovir-(TFV)-disoproxil-fumarate (TDF)/emtricitabine (FTC)-containing regimens, we found no significant correlation between hair concentrations of individual antiretrovirals (ARVs) in the regimen and measures of HIV persistence (plasma HIV-1 RNA by single copy assay, cell-associated-DNA, cell-associated RNA) or soluble markers of inflammation. These findings suggest that higher systemic ARV exposure may not impact HIV persistence or inflammation.

Indexed as

Viral LoadAdultAgedAnti-Retroviral AgentsCytokinesDNA, ViralFemaleHairHIV-1HIV InfectionsHumansInflammationLongitudinal StudiesMaleMiddle AgedRNA, ViralAnti-Retroviral AgentsCytokinesDNA, ViralRNA, Viral

Identifiers

PMID29529230
PMCPMC6009579
OpenAlexW2789975992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.